IMMUNOQUEST THERAPEUTICS AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board: OK
Ole Kristian Hjelstuen1962
Years since formation: 1 year; since Aug 15, 2023
Type: Limited company
VAT registered: No
Number of employees: 0

Ownership

Number of shares and share classes: 30,000; 1 share class
Total number of shareholders: 3; 1 company, 2 persons
Belongs to group of

Financials

Annual total result 2023: 3; NOK
Total equity 2023: 30,000; NOK

Last update: Aug 29, 2024

Management

Board

Name	Role	Shares
OK Ole Kristian Hjelstuen 1962	Chairman	-
MH Morten Hugo Egeberg 1969	Board Member	-
AP Anders Pablo Kapstad 1964	Board Member	-
KG Kari Grønås 1964	Board Member	-

Others

Name	Role	Shares
D DYNAMIK SMART ACCOUNTING AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
JA Jon Amund Kyte 1972	-	20 % directly
SE Seyed Esmaeil Dorraji 1983	-	13.33 % directly

Last update: Sep 12, 2024

Ownership

Company shareholders

Name	Share class	Number of shares	Share
I INVEN2 AS	Ordinary shares	20,000	66.67 %
JA Jon Amund Kyte 1972	Ordinary shares	6,000	20 %
SE Seyed Esmaeil Dorraji 1983	Ordinary shares	4,000	13.33 %

Last update: May 24, 2024

Group structure

INVEN2 AS
Total operating income 2023: NOK 81,985,000
Operating profit 2023: NOK -17,826,000
Employees: 32

Financials

in NOK

Summary

Year	2023
Total operating income	0
Annual Total Result	3
Total assets	30,000
Total liabilities	0
Total equity	30,000

P&L

Year	2023
Total operating income	0
Total operating costs	0
Operating result	0
Financial income/costs	3
Profit before tax	3
Total tax & extraordinary income/cost	0
Annual Total Result	3

Balance overview

Year	2023
Total fixed assets	0
Total current assets	30,000
Total assets	30,000
Short term debt	0
Long term debt	0
Total liabilities	0
Contributed capital	30,000
Retained earnings	0
Total equity	30,000
Total equity and liabilities	30,000

IMMUNOQUEST THERAPEUTICS AS931 892 266